The industry isn't growing. It's transforming. Here's what the data actually says — and what it means for your practice.
There’s a number floating around the aesthetic medicine industry that most medspa owners haven’t fully absorbed yet: $50 billion.
That’s was the estimated size of the U.S. aesthetic medicine market in 2025 — and depending on how broadly you define the category, estimates range from $25.47 billion (Precedence Research) to $49.28 billion (Nova One Advisor), with Grand View Research landing somewhere in the $38–44 billion range. The spread is wide because this market spans injectables, energy-based devices, surgical procedures, medical-grade skincare, and the facilities that deliver all of it.
Pick any of those numbers. They all tell the same story: aesthetic medicine is no longer a niche luxury. It is a mainstream, multi-generational, recession-resilient wellness category, and it is growing at a CAGR of between 9.7% and 13.4%.
The question isn’t whether the market is massive. It is. The question is whether your practice is positioned to capture a meaningful share of it.
The Medspa Boom Is Real and Still Accelerating
The most telling signal of where this market is headed isn’t the revenue number. It’s what’s happening at the ground level. According to the American Med Spa Association’s 2024 State of the Industry Report, the number of medspas in the United States grew from 8,899 in 2022 to 10,488 in 2023 with an expected increase to 13,000 by the end of 2026. That’s not organic growth. That’s a land grab.
The economics justify the expansion. Average annual revenue per medspa location has reached approximately $1.4 million, and the average patient spends $527 per visit. North America accounts for 36% to 55% of the entire global medical aesthetics market, making the United States the single largest national market in the world.
But here’s the number that should change how you think about your business model: 63% of medspa patients are now repeat visitors in high performing practices (QSight Medical Aesthetic Industry Trends, Jan 2026).
That is not a statistic you can overlook. That is a signal that aesthetic treatments are transitioning from discretionary, one-time expenditures to habitual lifestyle spending. Patients aren’t coming in for a special occasion anymore. They’re coming in on a schedule. They’re treating your services the way they treat a gym membership or a dental cleaning, as a routine part of maintaining how they look and feel. And if you build patient loyalty, you can shift your focus from patient acquisition to patient retention.
What’s Driving the Growth
Three structural forces are reshaping this market simultaneously, and understanding all three is essential if you want to build a practice that’s positioned for the next decade, not just this year.
First: The patient base is getting younger. Gen Z and Millennials are entering the aesthetic funnel earlier than any prior generation, driven by a philosophy of “prejuvenation,” preventive maintenance rather than corrective intervention. Guidepoint Qsight data shows Gen Z’s share of the aesthetic patient population grew from just 4% in 2017 to 10% in 2024. That shift doesn’t just add patients. It adds decades of lifetime value per patient.
Second: GLP-1 weight-loss medications are creating a new patient population. The mass adoption of drugs like Semaglutide and Tirzepatide has created predictable aesthetic consequences — facial volume loss, skin laxity, and body reshaping needs — that are driving demand for fillers, biostimulatory agents, and non-surgical body contouring at scale. Research published in the Journal of Cosmetic Dermatology confirms the clinical picture, and the ASPS’s 2024 data shows arm lifts, thigh lifts, and body reshaping procedures all trending upward.
Third: Private equity is consolidating the landscape. PE-backed platforms are professionalizing operations and accelerating geographic expansion, with expected consolidation of 15-20% of the market in the next 5 years. The competitive environment is intensifying and the practices that treat their operations like a business will outlast the ones that don’t.
The Recession-Proof Argument
One of the most important findings in recent market research is just how resilient aesthetic spending is during economic downturns. McKinsey’s research on the medical aesthetics market found that only 7% of aesthetic consumers expected to stop treatments entirely even in a recessionary scenario. The overwhelming majority said they might reduce frequency or trade down in treatment type, but they would not stop.
This is the investment thesis that’s attracting institutional capital to medical aesthetics. The consumer who has made aesthetic treatments part of their lifestyle is remarkably difficult to dislodge. They’ll reduce elsewhere before they cut here.
Understanding that fact should change how you think about patient acquisition. You’re not just selling a procedure. You’re converting someone into a long-term revenue relationship. Every new patient you acquire and retain has compounding value over the years they stay with you.
The Competitive Reality
Here’s what the expansion data also tells you: average medspa patient visit volumes have remained flat at approximately 245 per month despite the surge in total locations. More competition. Same pie per location.
That’s the reality. New medspas are opening everywhere, including in your market, your zip code, your strip mall. The practices winning in this environment aren’t the ones offering the most procedures or the lowest prices. They’re the ones with the strongest retention systems, the most compelling patient experience, and the operational infrastructure to manage growth without sacrificing quality.
BCG’s 2024 survey of 5,000 consumers across ten global markets estimates the total potential U.S. patient base at roughly 80 million consumers, with most procedure categories still in single-digit penetration of the population. That means the market isn’t saturated. But the supply of practices is growing faster than demand in many markets, which means differentiation matters more than it ever has. We rely on manufacturers to bring new patients into our specialty with their big advertising budget and loyalty programs, and the difference in market potential versus patient activation shows we still have massive opportunity.
What This Means for Your Practice Right Now
The medspa industry is at an inflection point. The structural tailwinds, aging population, younger patient entry, GLP-1 ripple effects, wellness normalization, are real and durable. The headwinds, intensifying competition, pricing pressure, rising patient acquisition costs, are equally real.
The practices that will dominate the next decade share a common set of characteristics: they treat patient retention as seriously as patient acquisition, they build membership and subscription models that create predictable monthly revenue, and they operate with the systems and data infrastructure that turn a clinical practice into a scalable business.
The $15 billion market is growing. The question is what will you do to increase how much of it lands in your practice?
Want to see how top-performing medspas are building the systems that drive retention and revenue growth? Learn more about our technology tools built specifically for medical aesthetics: LeadAR, your AI-powered growth engine designed to attract, convert, and retain patients, and Aesthetic Record, your end-to-end EMR and Practice Management software that keeps your practice compliant and streamlines operations while protecting your revenue.
